請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/22246
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 黃德富 | |
dc.contributor.author | Chia-Wen Chang | en |
dc.contributor.author | 張嘉文 | zh_TW |
dc.date.accessioned | 2021-06-08T04:14:20Z | - |
dc.date.copyright | 2010-09-13 | |
dc.date.issued | 2010 | |
dc.date.submitted | 2010-08-12 | |
dc.identifier.citation | Aggarwal BB., 2003. Signaling pathways of the TNF superfamily: A double-edged sword. Nat Rev Immunol. 3 (9): 745-756.
Akira S, Takeda K. ,2004. Toll-like receptor signalling. Nat Rev Immunol. 4(7):499-511. Alexander C, Rietschel ET. , 2001. Bacterial lipopolysaccharides and innate immunity. J Endotoxin Res. 7 (3): 167-202. Annetta M, Maviglia R, Proietti R, Antonelli M. , 2009. Use of corticosteroids in critically Ill septic patients: A review of mechanisms of adrenal insufficiency in sepsis and treatment. Curr Drug Targets. 10 (9): 887-894. Arbabi S, Maier RV. , 2002. Mitogen-activated protein kinases. Crit Care Med. 30 (1): Suppl. 74-79. Aruoma OI, Grootveld M, Bahorun T. , 2006. Free Radicals in biology and medicine: From inflammation to biotechnology. BioFactors. 27 (1-4): 1–3. Baldwin AS Jr. , 1996. The NF-kappa B and I kappa B proteins: new discoveries and insights. Annu Rev Immunol. 14: 649–683. Beck IM, Vanden Berghe W, Vermeulen L, Yamamoto KR, Haegeman G, De Bosscher K. , 2009. Crosstalk in Inflammation: The interplay of glucocorticoid receptor-based mechanisms and kinases and phosphatases. Endocr Rev. 30 (7): 830–882. Berger MM, Chioléro RL. , 2007. Antioxidant supplementation in sepsis and systemic inflammatory response syndrome. Crit Care Med. 35 (9): Suppl. 584-590. Bondeson, J. , 1997. The mechanisms of action of disease-modifying antirheumatic drugs: a review with emphasis on macrophage signal transduction and the induction of proinflammatory cytokines. Gen Pharmacol. 29 (2): 127–150. Born GV and Cross MJ. , 1963. The aggregation of blood platelets. J Physiol. 168 (1): 178-195. Boscá L, Zeini M, Través PG, Hortelano S., 2005. Nitric oxide and cell viability in inflammatory cells: a role for NO in macrophage function and fate. Toxicology. 208 (2): 249–258. Brown KD, Claudio E, Siebenlist U. , 2008. The roles of the classical and alternative nuclear factor-kappaB pathways: potential implications for autoimmunity and rheumatoid arthritis. Arthritis Res Ther. 10 (4): 212-226. Brown MD, Sacks DB. , 2008. Compartmentalised MAPK Pathways. Handb Exp Pharmacol. 186: 206-229. Burk DR, Senechal-Willis P, Lopez LC, Hogue BG, Daskalova SM. , 2009. Suppression of lipopolysaccharide-induced inflammatory responses in RAW264.7 murine macrophages by aqueous extract of Clinopodium vulgare L.(Lamiaceae). J Ethnopharmacol. 126 (3): 397–405S Castellheim A, Brekke OL, Espevik T, Harboe M, Mollnes TE. , 2009. Innate immune responses to danger signals in systemic inflammatory response syndrome and sepsis. Scand J Immunol. 69 (6): 479–491. Chan CC, Boyce S, Brideau C, Charleson S, Cromlish W, Ethier D, Evans J, Ford-Hutchinson AW, Forrest MJ, Gauthier JY, Gordon R, Gresser M, Guay J, Kargman S, Kennedy B, Leblanc Y, Leger S, Mancini J, O'Neill GP, Ouellet M, Patrick D, Percival MD, Perrier H, Prasit P, Rodger I, et al. 1999. Rofecoxib [Vioxx, MK-0966; 4-(4'-methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone]: a potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles. J Pharmacol Exp Ther. 290 (2): 551-560. Chang L, Karin M. , 2001. Mammalian MAP kinase signalling cascades. Nature. 410 (6824): 37-40. Chen K, Pittman RN, Popel AS., 2008. Nitric oxide in the vasculature: where does it come from and where does it go? A quantitative perspective. Antioxid Redox Signal. 10 (7):1185–1198. Cobb MH. , 1999. MAP kinase pathways. Progress in Biophysics & Molecular Biology 71 (3):479-500. Cohen J. , 2002. The immunopathogenesis of sepsis. Nature. 420: 885-891. Coussens LM, Werb Z. , 2002. Inflammation and cancer. Nature. 420: 860-867. Crosswhite P, Sun Z. , 2010. Nitric oxide, oxidative stress and inflammation in pulmonary arterial hypertension. J Hypertens. 28 (2):201-212. Demedts M, Behr J, Buhl R, Costabel U, Dekhuijzen R, Jansen HM, MacNee W, Thomeer M, Wallaert B, Laurent F, et al, 2005. High-dose acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med. 353 (21):2229-2242. Dileepan KN, Page JC, Li Y, Stechschulte DJ. 1995. Direct activation of murine peritoneal macrophages for nitric oxide production and tumor cell killing by interferon-γ. J Interferon Cytokine Res. 15(5):387-394. Eberlein M, Scheibner KA, Black KE, Collins SL, Chan-Li Y, Powell JD, Horton MR. , 2008. Anti-oxidant inhibition of hyaluronan fragment-induced inflammatory gene expression. Journal of Inflamm. 5:20. English JM, Cobb MH. , 2002. Pharmacological inhibitors of MAPK Pathways. Trends Pharmacol Sci. 23 (1): 40-45. Fabio Martinon, 2010. Signaling by ROS drives inflammasome activation. Eur J Immunol. 40 (3): 616-9. Fernandes JC, Martel-Pelletier J, Pelletier JP. , 2002. The role of cytokines in osteoarthritis pathophysiology. Biorheology 39 (1-2): 237–246. Firestein GS. , 2003. Evolving concepts of rheumatoid arthritis. Nature 423: 356-361. Ghosh S, May MJ, Kopp EB. , 1998. NF-kappa B and Rel proteins: evolutionarily conserved mediators of immune responses. Annu Rev Immunol. 16: 225–260. Glaros T, Larsen M, Li L. , 2009. Macrophages and fibroblasts during inflammation, tissue damage and organ injury. Front Biosci. 14: 3988-3993. Goldring MB, Goldring SR. , 2007. Osteoarthritis. J Cell Physiol. 213: 626–634. Gordon S, Taylor PR. , 2005. Monocyte and macrophage heterogeneity. Nat Rev Immunol. 5: 953-964. Guerne PA, Zuraw BL, Vaughan JH, Carson DA, Lotz M. , 1989. Synovium as a source as interleukin-6 in vitro: Contribution to local and systemic manifestations of arthritis. J. Clin Invest. 83 (2): 585–592. Guha M, Mackman N. , 2001. LPS induction of gene expression in human monocytes. Cell Signal. 13 (2): 85–94. Hatzelmann A, Schudt C. , 2000. Anti-Inflammatory and Immunomodulatory Potential of the Novel PDE4 Inhibitor Roflumilast in Vitro. J Pharmacol Exp Ther. 297 (1): 267-279. Hayden MS, Ghosh S. , 2004. Signaling to NF-kappaB Genes Dev. 18 (18): 2195-2224. Heo, S.K., Yun, H.J., Noh, E.K., Park, W.H., Park, S.D., 2008. LPS induces inflammatory responses in human aortic vascular smooth muscle cells via Toll-like receptor 4 expression and nitric oxide production. Immunol Lett. 120 (1-2): 57–64. Hernández-Ledesma B, Hsieh CC, de Lumen BO. , 2009. Antioxidant and anti-inflammatory properties of cancer preventive peptide lunasin in RAW 264.7 macrophages. Biochem Biophys Res Commun. 390 (3): 803–808. Hsu HY, Wen MH. , 2002. Lipopolysaccharide-mediated reactive oxygen species and signal transduction in the regulation of interleukin-1 gene expression. J Bio Chem. 277 (25): 22131-22139 Janssen-Heininger YM, Poynter ME, Baeuerle PA. , 2000. Recent advances towards understanding redox mechanisms in the activation of nuclear factor kappaB. Free Radic Bio Med. 28 (9): 1317–1327. Jaulmes A, Janvier B, Andreani M, Raymondjean M. , 2005. Autocrine and paracrine transcriptional regulation of type II A secretory phospholipase A2 gene in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol. 25 (6): 1161– 1167. Johnson GL, Lapadat R., 2002. Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science. 298 (5600): 1911–1912. Kamimura D, Ishihara K, Hirano T. , 2003. IL-6 signal transduction and its physiological roles: the signal orchestration model. Rev Physiol Biochem Pharmacol. 149:1–38. Kawai T, Akira S. , 2007. Signaling to NF-kappaB by Toll-like Receptors. Trends Mol Med. 13 (11): 460-469. Kim EK, Choi EJ. , 2010. Pathological roles of MAPK signaling pathways in human diseases. Biochim Biophys Acta 1802 (4): 396–405. Kim JB, Han AR, Park EY, Kim JY, Cho W, Lee J, Seo EK, Lee KT. , 2007. Inhibition of LPS-induced iNOS, COX-2 and cytokines expression by poncirin through the NF-kappaB inactivation in RAW 264.7 macrophage cells. Biol Pharm Bull. 30 (12): 2345-2351. Kim MO, Moon DO, Jung JM, Lee WS, Choi YH and Kim GY, 2009. Agaricus blazei Extract Induces Apoptosis through ROS-dependent JNK Activation Involving the Mitochondrial Pathway and Suppression of Constitutive NF-kappaB in THP-1 Cells. Evid Based Complement Alternat Med. :1-9 Kim YJ, Hwang SY, Oh ES, Oh S, Han IO. , 2006. IL-1beta, an immediate early protein secreted by activated microglia, induces iNOS/NO in C6 astrocytoma cells through p38 MAPK and NF-kappaB pathways. J Neurosci Res. 84 (5): 1037–1046. Konecki E, Ehrlich YH, De Mars DD and Lenox RH., 1986. Exposure of fibrinogen receptors in human platelets by surface proteolysis with elastase. J Clin Invest. 77 (3): 750-756. Kraus S, Arber N. , 2009. Inflammation and colorectal cancer. Curr Opin Pharmacol. 9(4): 405–410. Laskin DL, Pendino KJ. , 1995. Macrophages and inflammatory mediators in tissue injury. Annu Rev Pharmacol Toxicol. 35: 655-677. Ley K, Laudanna C, Cybulsky MI, Nourshargh S. , 2007. Getting to the site of inflammation: the leukocyte adhesion cascade updated. Nat Rev Immunol. 7 (9): 678-689. Li Q, Verma IM. , 2002. NF-κB regulation in the immune system. Nat Rev Immunol. 2 (10): 725-734. Liang Y, Zhou Y, Shen P. , 2004. NF-kappaB and its regulation on the immune system. Cell Mol Immunol. 1(5):343-350. Liu K, Waskow C, Liu X, Yao K, Hoh J, Nussenzweig M. , 2007. Origin of dendritic cells in peripheral lymphoid organs of mice. Nat Immunol. 8 (6): 578–583. Liu YL, Lin HM, Zou R, Wu JC, Han R, Raymond LN, Reid PF, Qin ZH. , 2009. Suppression of complete Freund’s adjuvant-induced adjuvant arthritis by cobratoxin. Acta Pharmacol Sin. 30 (2): 219–227 López-Novoa JM, Nieto MA. , 2009. Inflammation and EMT: an alliance towards organ fibrosis and cancer progression. EMBO Mol Med. 1 (6-7): 303–314. Luiking YC, Engelen MP, Deutz NE. , 2010. Regulation of nitric oxide production in health and disease. Curr Opin Clin Nutr Metab Care. 13 (1):97–104. Mantovani A, Allavena P, Sica A, Balkwill F. , 2008. Cancer- related inflammation. Nature. 454: 436-444. Mathews CJ, Weston VC, Jones A, Field M, Coakley G. , 2010. Bacterial septic arthritis in adults. Lancet. 375 (9717): 846–855. Medzhitov R. , 2008. Origin and physiological roles of inflammation. Nature. 454 (7203): 428-435. Miyake K. , 2004. Endotoxin recognition molecules, Toll-like receptor 4-MD-2. Semin Immunol. 16 (1): 11–16. Moncada, S., 1999. Nitric oxide: discovery and impact on clinical medicine. J R Soc Med. 92 (4), 164–169. Moynagh PN. , 2005. The NF-kappaB pathway. J Cell Sci. 118 (20): 4389-4392. Nagata M. , 2005. Inflammatory Cells and Oxygen Radicals. Curr Drug Targets Inflamm Allergy. 4 (4): 503-504. Nathan C, 2002. Points of control in inflammation. Nature. 420 (6917): 846–852. Nathan, C., 1992. Nitric oxide as a secretory product of mammalian cells. The FASEB J. 6 (12), 3051–3064. Nietfeld JJ, Wilbrink B, Helle M, van Roy JL, den Otter W, Swaak AJ, Huber-Bruning O. , 1990. Interleukin-1-induced interleukin-6 is required for the inhibition of proteoglycan synthesis by interleukin-1 in human articular cartilage. Arthritis Rheum. 33 (11): 1695–1701. Paleolog EM. , 2002. Angiogenesis in rheumatoid arthritis. Arthritis Res. 4 (suppl 3): S81-S90. Pan JS, Hong MZ, Ren JL. , 2009. Reactive oxygen species: A double-edged sword in oncogenesis. World J Gastroenterol. 15 (14): 1702-1707. Pearson G, Robinson F, Beers Gibson T, Xu BE, Karandikar M, Berman K, Cobb MH. , 2010. Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions. Endocr Rev. 22 (2): 153–183. Pereira SG, Oakley. , 2008. Nuclear factor-kappaB: Regulation and function. The International Journal of Biochemistry & Cell Biology 40: 1425–1430. Porta C, Larghi P, Rimoldi M, Totaro MG, Allavena P, Mantovani A, Sica A. , 2009. Cellular and molecular pathways linking inflammation and cancer. Immunobiology. 214 (9-10): 761–777. Raman M, Chen W, Cobb MH. , 2007. Differential regulation and properties of MAPKs. Oncogene. 26 (22): 3100–3112. Rinaldi S, Landucci F, De Gaudio AR. , 2009. Antioxidant therapy in critically septic patients. Curr Drug Targets. 10 (9): 872-880. Rocca B, FitzGerald GA, 2002. Cyclooxygenases and prostaglandins: shaping up the immune response. Int Immunopharmacol. 2 (5): 603–30. Sanlioglu S, Williams CM, Samavati L, Butler NS, Wang G, McCray PB Jr, Ritchie TC, Hunninghake GW, Zandi E, Engelhardt JF. , 2001. Lipopolysaccharide induces Rac1-dependent reactive oxygen species formation and coordinates tumor necrosis factor-alpha Secretion through IKK Regulation of NF-kappaB . J Bio Chem. 276 (32): 30188– 30198. Schetter AJ, Heegaard NH, Harris CC. , 2010. Inflammation and cancer: interweaving microRNA, free radical, cytokine and p53 pathways. Carcinogenesis. 31 (1): 37- 49. Semple JW, Freedman J. , 2010. Platelets and innate immunity. Cell Mol Life Sci. 67 (4):499–511. Singh VP, Patil CS, Jain NK, Kulkarni SK, 2004. Aggravation of inflammatory bowel disease by cyclooxygenase-2 inhibitors in rats. Pharmacology. 72 (2): 77–84. Soehnlein O, Zernecke A, Eriksson EE, Rothfuchs AG, Pham CT, Herwald H, Bidzhekov K, Rottenberg ME, Weber C, Lindbom L. , 2008. Neutrophil secretion products pave the way for inflammatory monocytes. Blood. 112 (4): 1461-1471. Swindle EJ, Metcalfe DD. , 2007. The role of reactive oxygen species and nitric oxide in mast cell dependent inflammatory processes. Immunol Rev. 217: 186–205. Taylor PC, Feldmann M. , 2009. Anti-TNF biologic agents: still the therapy of choice for rheumatoid arthritis. Nat Rev Rheumatol. 5 (10): 578–582. Thalhamer T, McGrath MA, Harnett MM. , 2008. MAPKs and their relevance to arthritis and inflammation. Rheumatology. 47 (4): 409–414. Torphy TJ., 1998. Phosphodiesterase isozymes-molecular targets for novel antiasthma agents. Am J Respir Crit Care Med. 157 (2): 351–370. Toussaint S, Gerlach H. , 2009. Activated Protein C for Sepsis. N Engl J Med. 361 (27): 2646-2652. Turini ME, DuBois RN, 2002. Cyclooxygenase-2: a therapeutic target. Annu Rev Med. 53: 35–57. van Furth R, Cohn ZA. , 1968. The origin and kinetics of mononuclear phagocytes. J Exp Med. 128 (3): 415–435. Wong ET, Tergaonkar V. , 2009. Roles of NF-κB in health and disease: mechanisms and therapeutic potential. Clin Sci. 116 (6): 451–465. Xiao G, Rabson AB, Young W, Qing G, Qu Z. , 2006. Alternative pathways of NF-kB activation: A double-edged sword in health and disease. Cytokine Growth Factor Rev. 17 (4): 281–293. Xiao W. , 2004. Advances in NF-κB signaling transduction and transcription. Cell Mol Immunol. 1(6):425-435. Xie QW, Kashiwabara Y, Nathan C., 1994. Role of transcription factor NF-kappa B/Rel in induction of nitric oxide synthase. J Biol Chem. 269: 4705–4708. Yen YT, Liao F, Hsiao CH, Kao CL, Chen YC, Wu-Hsieh BA. 2006. Modeling the early events of severe acute respiratory syndrome coronavirus infection in vitro. J Virol. 80(6):2684-2693. Yona S, Jung S. , 2010. Monocytes: subsets, origins, fates and functions. Curr Opin Hematol. 17 (1): 53–59. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/22246 | - |
dc.description.abstract | 發炎反應(Inflammation)為組織受傷或受微生物侵入時,體內所產生的自然防禦機制,一般具有紅、腫、熱、痛之典型特徵,引起微血管擴張、血流加速、血管通透性增加及白血球移行(migrate)至發炎部位,進而吞噬或稀釋病原體及受傷組織。在發炎反應的過程中,活化的免疫細胞還會分泌多種具有細胞毒殺作用(cytotoxic)或促發炎反應的細胞激素(proinflammatory cytokine)來促進並維持發炎反應的進行以助於個體清除外來的有害刺激,然而;在過度的發炎反應中,上述物質會大量產生而對個體產生傷害。近來研究指出,發炎反應和多種疾病狀態有關,例如:關節炎、阿茲海默症、多發性硬化症、氣喘、動脈硬化、自體免疫疾病、癌症甚至是急性的敗血症。因此;尋找具有抗發炎活性的藥物來抑制過度的發炎反應便成為藥物開發的重要方向。在初步的藥物活性篩選過程中,我們發現化合物yuwen02f1具有抗發炎活性,並且在活性測試所使用的劑量下,不會影響細胞的存活率。實驗指出化合物yuwen02f1在30 μM時即可有效抑制受細菌內毒素(LPS)活化的鼠源巨噬細胞或人類的單核細胞所分泌的細胞激素,像是TNF-α及IL-6;也會抑制nitric oxide及自由基(ROS)的釋放,甚至抑制發炎反應過程中重要的移行現象。在活體實驗中,我們使用了敗血症動物模式來模擬急性發炎也用關節炎動物模式來模擬慢性發炎,藉此研究化合物yuwen02f1在急性及慢性發炎中的抗發炎活性。我們發現不論是在急、慢性發炎中,此化合物都具有抑制發炎的現象,例如:有效降低敗血症小鼠血清中的發炎細胞激素含量(TNF-α與IL-6)、降低LPS誘發敗血症小鼠之死亡率、改善敗血症小鼠所受到的器官損傷及血小板低下症,甚至是抑制關節炎小鼠的足腫現象。在機制的探討方面,LPS活化巨噬細胞後所產生的下游訊息傳遞鏈以MAPK路徑及NF-κB路徑為主。在MAPK 路徑中,我們檢視了三種重要的激酶包括p-38、ERK1/2、JNK的磷酸化現象,發現化合物yuwen02f1對於這三種激酶的磷酸化都有抑制作用;另外也檢視了NF-κB活化路徑中重要的因子:IκB的降解(degradation)情形,發現化合物yuwen02f1也可將此降解現象反轉回來;此外,yuwen02f1也可從轉錄層級(transcriptional level)去抑制活化NF-κB路徑後所誘發的下游酵素,例如:iNOS及COX-2的表現。因此我們推測化合物yuwen02f1藉由抑制這兩條訊息傳遞路徑來抑制發炎反應。 | zh_TW |
dc.description.abstract | Inflammation, usually characterized by swelling, redness, pain, and heat, is a crucial function of the innate immune system and it is necessary to protect the host against pathogens and to initiate specific immunity. Upon bacterial invasion, mammalian monocytes/ macrophages release a variety of inflammatory mediators such as pro-inflammatory and cytotoxic cytokines, chemokines and reactive oxygen/nitrogen species to defense harmful stimuli, but excessive inflammatory reaction leads to extensive tissue damage and manifestation of pathological states such as multiple sclerosis, asthma, arthritis, atherosclerosis, Alzheimer’s disease and cancer. Therefore, targeting on uncontrolled inflammation seems feasible to control numerous inflammation-associated diseases. Under the drug screening process of 5250 derivatives, we discovered compound yuwen02f1, a synthetic phenylpyrazole compound, possesses anti-inflammatory effects in decreasing the release of pro-inflammatory cytokines including TNF-α and IL-6, nitric oxide, reactive oxygen species (ROS) as well as inhibiting migration of LPS-stimulated phagocytes, and we also excluded its cytotoxicity by cell viability and LDH release assay. Furthermore, we found that yuwen02f1 attenuates some pathological syndromes of LPS-induced sepsis and adjuvant-induced arthritis in mice, such as decreasing the cytokine production, reversing thrombocytopenic syndrome, protecting the mice from tissue injury in septic mice and attenuating paw edema in arthritic mice as well. These results suggest the beneficial effects of yuwen02f1 both on acute and chronic inflammation. In protein expression of LPS-stimulated macrophages, we observed that the molecular mechanism of yuwen02f1-mediated anti-inflammation is associated with decreasing phosphorylation of MAPK molecules such as ERK1/2, JNK and p38. Yuwen02f1 also reverses IκB degradation and attenuates the expression of NF-κB-related downstream inducible enzymes like iNOS and COX-2. These results indicate that yuwen02f1 inhibits LPS-stimulated inflammation through the blockade of NF-κB and MAPK pathways. | en |
dc.description.provenance | Made available in DSpace on 2021-06-08T04:14:20Z (GMT). No. of bitstreams: 1 ntu-99-R97443002-1.pdf: 2735718 bytes, checksum: e868e4af424ada6f9377337b976200e9 (MD5) Previous issue date: 2010 | en |
dc.description.tableofcontents | 中文摘要………………………………………………………………i
Abstract ……………………………………………………………iii Abbreviation table………………………………………………… v Chapter 1 Introduction…………………………………………… 1 1.1 Overview of inflammation…………………………………… 1 1.2 Role of leukocytes in inflammation……………………… 2 1.3 Macrophage-derived cytotoxic and proinflammatory mediators………………………………………………………………4 1.3.1 Inflammatory cytokines………………………………………4 1.3.2 Nitric oxide (NO)…………………………………………… 7 1.3.3 Reactive oxygen species…………………………………… 8 1.4 The signaling pathways of lipopolysaccharide (LPS)… 9 1.4.1 The MAP kinase pathway…………………………………… 10 1.4.2 The NF-κB pathway……………………………………………11 1.5 Sepsis…………………………………………………………… 13 1.6 Arthritis…………………………………………………………14 1.7 Cancer…………………………………………………………… 16 1.8 Yuwen02f1…………………………………………………………18 Chapter 2 Materials and methods…………………………………28 2.1 Materials…………………………………………………………28 2.2 Cell cultures……………………………………………………28 2.2.1 Cell culture – RAW 264.7 macrophage cell……………28 2.2.2 Cell culture – Murine peritoneal macrophage cell…29 2.2.3 Cell culture – Human THP-1 monocytic leukemia cell……………………………………………………………………29 2.3 Cytokine assays…………………………………………………30 2.4 Nitric oxide assay…………………………………………… 31 2.5 ROS measurement…………………………………………………31 2.6 Cell viability assay………………………………………… 32 2.7 LDH release assay………………………………………………33 2.8 Migration assay ……………………………………………… 33 2.9 Western blot analysis…………………………………………34 2.10 In vivo assay …………………………………………………35 2.10.1 Animals………………………………………………………35 2.10.2 Acute inflammation model: LPS- induced sepsis……36 2.10.2.1 LPS challenge……………………………………………36 2.10.2.2 Mice whole blood and plasma collection……………36 2.10.2.3 Measurement of cytokine levels………………………36 2.10.2.4 Histological examination..……………………………37 2.10.3 Chronic inflammation model: adjuvant- induced arthritis………………………………………………………………37 2.10.3.1 Induction of arthritis…………………………………37 2.10.3.2 Yuwen02f1 treatment and evaluation of arthritis………………………………………………………………37 2.10.3.3 Histological examination………………………………38 2.11 Statistical analysis…………………………………………38 Chapter 3 Results……………………………………………………39 3.1 The exploration of anti-inflammatory lead compound from 5250- derivatives…………………………………………… 39 3.2 Yuwen02f1 inhibits pro-inflammatory cytokines like TNF-α and IL-6 production in LPS-stimulated phagocytes……… 39 3.3 Yuwen02f1 inhibits nitric oxide production and iNOS expression in LPS- stimulated RAW264.7 macrophages……… 40 3.4 Yuwen02f1 inhibits COX-2 expression in LPS-stimulated RAW 264.7 cells………………………………………………………41 3.5 Yuwen02f1 inhibits ROS production in LPS-stimulated RAW 264.7 macrophages……………………………………………………………41 3.6 Cytotoxicity of yuwen02f1 on murine macrophages in vitro and ex vivo……………………………………………………42 3.7 Yuwen02f1 inhibits the migration of LPS-stimulated murine macrophages and human monocytes………………………42 3.8 Yuwen02f1 inhibits the phosphorylation of MAPK molecules in LPS- stimulated RAW 264.7 cells……………… 43 3.9 Yuwen02f1 inhibits IκBα degradation in LPS-induced RAW264.7 macrophages……………………………………………… 43 3.10 The effects of yuwen02f1 on acute inflammation in vivo…………………………………………………………………… 44 3.10.1 Yuwen02f1 inhibits pro-inflammatory cytokines including TNF-α and IL-6 production in vivo…………………45 3.10.2 Yuwen02f1 reverses LPS-induced thrombocytopenia…45 3.10.3 Effects of yuwen02f1 on tissue injury in endotoxemia examined by histochemistry……………………… 46 3.11 The effects of yuwen02f1 on chronic inflammation in vivo…………………………………………………………………… 46 3.11.1 Yuwen02f1 attenuates paw edema caused by adjuvant-induced arthritis……………………………………………………47 3.11.2 The effects of yuwen02f1 on histopathology of adjuvant-induced arthritis……………………………………… 47 Chapter 4 Discussion………………………………………………71 Chapter 5 Conclusion and Perspectives…………………………76 References……………………………………………………………78 | |
dc.language.iso | en | |
dc.title | 化合物yuwen02f1之抗發炎作用及機轉之探討 | zh_TW |
dc.title | The anti-inflammatory effects and mechanisms of compound yuwen02f1 | en |
dc.type | Thesis | |
dc.date.schoolyear | 98-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 鄧哲明,顏茂雄,楊春茂,吳文彬 | |
dc.subject.keyword | 發炎反應,巨噬細胞,敗血症,足腫現象,細菌內毒素, | zh_TW |
dc.subject.keyword | inflammation,macrophage,sepsis,paw edema,lipopolysaccaride,NF-kappaB, | en |
dc.relation.page | 90 | |
dc.rights.note | 未授權 | |
dc.date.accepted | 2010-08-12 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 藥理學研究所 | zh_TW |
顯示於系所單位: | 藥理學科所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-99-1.pdf 目前未授權公開取用 | 2.67 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。